Brief: Dermapharm Holding Sees 2024 Adjusted Consolidated EBITDA Between EUR 305 And Eur 315 Mln

Dermapharm Holding SE

14/03/2024 06:33

March 14 (Reuters) - DERMAPHARM HOLDING SE  DMPG.DE :
    * HITS UPPER END OF GUIDANCE RANGE FOR ADJUSTED EBITDA,
PRIMARILY
DUE TO STEADILY GROWING INTERNATIONAL PRESENCE IN BRANDED
BUSINESS
    * BOARD OF MANAGEMENT PROPOSES DIVIDEND OF EUR 0.88 PER
SHARE AT
ANNUAL GENERAL MEETING
    * FURTHER REVENUE AND EBITDA GROWTH EXPECTED IN 2024
    * BOARD OF MANAGEMENT EXPECTS CONSOLIDATED REVENUE TO
INCREASE TO
BETWEEN EUR 1,170 MILLION AND EUR 1,210 MILLION IN CURRENT 2024
FINANCIAL YEAR
    * ADJUSTED CONSOLIDATED EBITDA IS EXPECTED TO AMOUNT TO
BETWEEN
EUR 305 MILLION AND EUR 315 MILLION

Source text for Eikon:  ID:nEQ4ds4GXa 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))